Use of heparin during acute myocardial infarction in routine clinical practice in Germany - Results of the MITRA and MIR registries;Stellenwert des heparins in der aktuellen therapie des akuten myokardinfarktes in Deutschland - Ergebnisse der MITRA-und MIR-register

Zeitschrift fur Kardiologie

Volumn 91, Issue 2, 2002, Pages 131-138

  Frilling, Birgit ^a   Schiele, R ^a   Zahn, R ^a   Fischer, F ^a   Schneider, S ^a   Gitt, A K ^a   Heer, T ^a   Gottwik, M ^b   Glunz, H G ^c   Gieseler, U ^d   Baumgartel B ^e   Asbeck, F ^f   Senges, J ^g  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c Westpfalz Klinikum GmbH   (Germany)

^d Diakonissenkrankenhaus Speyer   (Germany)

^e Kreiskrankenhaus Freital   (Germany)

^f Stadtisches Krankenhaus Kiel   (Germany)

^g NONE

Author keywords

Acute myocardial infarction; Fibrinolysis; Heparin

Indexed keywords

HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; FIBRINOLYTIC THERAPY; GERMANY; HEART MUSCLE REPERFUSION; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0036185738     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920200002     Document Type: Article

References (17)

1. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
2. Six-months survival in 20891 patients with acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
3. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs asprin alone among 41 299 cases of suspected acute myocardial infarction
4. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
5. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither, among 17 181 cases of suspected acute myocardial infarction: ISIS-2
6. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infartion
7. 1999 Update: ACC/AHA guidelines for the management of patients wiht acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction)
8. MITRA: Maximal individual therapy in acute myocardial infarction is associated with a lower hospital mortality
9. Frühbehandlung des akuten myokardinfarktes. Umsetzung von therapierichtlinien in den klinischen alltag
10. Akuter myokardinfarkt in Deutschland 1998: Therapie und hospitaler verlauf. Das myokardinfarktregister (MIR) in Deutschland
11. Physicianś use of heparin following thrombolytic therapy: An international perspective
12. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction
13. Use and effectiveness of intravenous heparin therapy for treatment of acute myocardial infarction in the elderly
14. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy
15. Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy
16. Low molecular weight heparin (Dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction-a pilot study: Biochemical markers in acute coronary syndroms (BIOMACS II)
17. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction